NCT01895127View on ClinicalTrials.gov

Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Antibody-mediated RejectionHumoral Rejection
Interventions
DRUG

Eculizumab

BIOLOGICAL

Immunoglobulin

PROCEDURE

Plasmapheresis

Trial Locations (3)

48109

University of Michigan Medical Center, Ann Arbor

94122

UCSF Medical Center, San Francisco

02115

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Alexion Pharmaceuticals, Inc.

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT01895127 - Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation | Biotech Hunter | Biotech Hunter